NCT04697810Phase 2Unknown

Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-04-15Estimated

Enrollment · participants114Estimated

Source updated2024-07-31Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

NASH - Nonalcoholic Steatohepatitis

Treatments or interventions studied

NamodenosonDrugAlso known as CF102
PlaceboDrugAlso known as Inactive control

Primary outcomes · main study measures

measure: Non-Alcoholic Fatty Liver Disease (NAFLD) activity score (NAS); description: Proportion of subjects who achieve a ≥2-point improvement in the non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of the Non-Alcoholic Steatohepatitis Clinical Research Network (NASH CRN); timeFrame: 36 weeks; measure: Adverse events (AEs); description: Incidence of AEs; timeFrame: 36 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history